On the surface, GlaxoSmithKline plc (ADR) (NYSE:GSK)'s release of phase 2 data on drisapersen looks like good news for Sarepta Therapeutics Inc (NASDAQ:SRPT)'s competing Duchenne...
Keep Reading →
August 17 - News
Even with the broad-based S&P 500 retracing for three straight days amid worries that the Federal Reserve may begin paring back its monthly bond-buying program as early as next...
Keep Reading →
August 9 - News
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug.
Keep Reading →
August 8 - News
Economic problems and worries? We'll have none of those here, says the Nasdaq Composite, which soared to a fresh 12-year high on this week's news that the Federal Reserve is no...
Keep Reading →
August 5 - News
Today, let's look at Tocqueville Asset Management, a portfolio manager with a contrarian bent, believing that "the best investment results over time are achieved outside the...
Keep Reading →
August 2 - Hedge Funds
The global biotechnology industry is expected to reach $320 billion by 2015, up from $232 billion in 2012.
Keep Reading →
August 1 - News
This week's list of the most horrendous health-care stocks is brought to you by the letter "S." Just like on Sesame Street, all of the names we will discuss start with the same...
Keep Reading →
July 29 - News
The study included 184 patients with mild-to-moderate persistent allergic asthma.
Keep Reading →
July 29 - News
Investors wondered for months if Sarepta Therapeutics Inc (NASDAQ:SRPT) would pursue accelerated approval for Duchenne muscular dystrophy, or DMD, drug eteplirsen.
Keep Reading →
July 25 - News
If you thought the fireworks ended after the Fourth of July celebrations last week, think again.
Keep Reading →
July 15 - News
A year ago, AVI BioPharma underwent a process from being an $85 million biotechnology company to a $1.3 billion company called Sarepta Therapeutics Inc (NASDAQ:SRPT).
Keep Reading →
July 15 - News
Last year, these three stocks weren’t even on the radar of most retail investors, but have since returned incredible gains.
Keep Reading →
July 1 - News
Today, let's look at Viking Global Investors, founded in 1999 by Andreas Halvorsen and David Ott, who had previously worked together at Julian Robertson's respected Tiger Management...
Keep Reading →
June 27 - Hedge Funds
One implication of the principle of diversification is that company insiders- who, in a way, are already “invested” in the company as it is a source of income for them- should...
Keep Reading →
June 25 - Insider Trading
The easiest route would involve the companies with the biggest share price movements.
Keep Reading →
June 25 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer. Its one potential challenger...
Keep Reading →
June 18 - News
The healthcare industry is slowly becoming what the pre-crash technology industry was of the early 2000's.
Keep Reading →
June 18 - News
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Keep Reading →
June 13 - News
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Keep Reading →
June 12 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Keep Reading →
June 10 - News
If you heeded the old adage to "sell in May and go away" this year, you're probably second-guessing your decision now.
Keep Reading →
June 6 - News
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
Keep Reading →
June 3 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Keep Reading →
June 3 - News
Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 31 - News
Shaw is known as a math wizard, and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants -- and Amazon.com, Inc.
Keep Reading →
May 31 - Hedge Funds
You have plenty of choices of where to invest your portfolio.
Keep Reading →
May 31 - News
George Soros is known to some folks these days for his politics and philanthropy, but his fame stems from his wealth, which is a result of his outstanding investing prowess.
Keep Reading →
May 23 - Hedge Funds
Huge fortunes are won and lost in the world of biotech nearly every week. For those new to this world, it can appear both alluring and scary.
Keep Reading →
May 22 - News
The words of the great big-band leader Duke Ellington came to mind after hearing the first quarter results from Sarepta Therapeutics Inc (NASDAQ:SRPT) : "It don't mean a thing...
Keep Reading →
May 9 - News
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has faced the affects of bad press more than once in the past.
Keep Reading →
May 8 - News
Leading health-care stocks have had a good start to the year, but all's not healthy in the world of medicine.
Keep Reading →
May 4 - News
Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they're more like $12 billion or more a dozen, but you get the point.
Keep Reading →
April 23 - News
They're demanding. They take risks -- but only calculated ones. And they ask lots of penetrating questions to understand as much as possible before putting a dime on the line.
Keep Reading →
April 22 - News
Let's start with Magnum Hunter Resources. Investors bailed on Magnum Hunter after the oil and gas explorer bailed on its auditor.
Keep Reading →
April 21 - News
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 20 - News
At the moment, there are dozens of methods market participants can use to monitor publicly traded companies. Some of the best are hedge fund and insider trading sentiment.
Keep Reading →
April 19 - News
A lot has been written this week -- at The Fool and elsewhere -- about Sarepta Therapeutics Inc (NASDAQ:SRPT)' update on its meeting with the Food and Drug Administration.
Keep Reading →
April 18 - News
So much for the big correction.
Keep Reading →
April 17 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
April 16 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced yesterday after the market closed that the U.S.
Keep Reading →
April 16 - News
There is always something interesting happening in the Bio-Pharma sector due to a number of firms working on several new drugs.
Keep Reading →
April 16 - News
The Dow Jones Industrial Average (Dow Jones Indices:.DJI) flashed a 60-point gain yesterday driven higher by the tech sector and its old dynamic duo, Microsoft Corporation (NASDAQ...
Keep Reading →
April 10 - News
You can find investment ideas in the strangest places. Take Obamacare, for example.
Keep Reading →
April 5 - News
They don't have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail.
Keep Reading →
April 4 - News
With the Nasdaq Biotechnology Index hitting record highs, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about whether we're in...
Keep Reading →
March 22 - News
When building your portfolio, aim for diversification. You should aim to hold both large and small companies (plus mid-sized ones) and companies in a range of industries.
Keep Reading →
March 20 - News
As first-quarter earnings begin to wind down, I can't help but point out that the majority of earnings reports we've covered over the past year have been better than expected.
Keep Reading →
March 11 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) was on fire in 2012, landing at the top of the list of The Motley Fool's best health-care stocks of the year.
Keep Reading →
March 7 - News
On Monday, Depomed Inc (NASDAQ:DEPO) is expected to go before the FDA panel with its menopausal hot-flash drug, Serada.
Keep Reading →
March 4 - News
George Soros is known to some folks these days for his politics and philanthropy, but his fame stems from his wealth, which is a result of his outstanding investing prowess.
Keep Reading →
February 20 - Hedge Funds
